Advancing Science to Improve Lives Worldwide

Zhenzhu Pharma is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that address serious unmet medical needs.

15+
Pipeline Programs
50M+
Patients Reached
30+
Countries
2,500+
Employees
FDA Approved Facilities
GMP Certified
ISO 9001:2015
EMA Compliant

Therapeutic Areas

We focus on areas of high unmet medical need where we can make the greatest impact for patients.

Cardiovascular

Developing treatments for heart failure, hypertension, and related conditions.

Learn more

Oncology

Pioneering targeted therapies and immunotherapies for various cancers.

Learn more

Immunology

Creating innovative treatments for autoimmune and inflammatory diseases.

Learn more

Neuroscience

Advancing therapies for neurological and psychiatric disorders.

Learn more

Our Pipeline

A robust portfolio of investigational medicines across multiple therapeutic areas and modalities.

Program
Indication
Preclinical
Phase 1
Phase 2
Phase 3
ZZP-101 Small molecule
Breast Cancer
Active
ZZP-205 Monoclonal antibody
Heart Failure
Active
ZZP-318 Bispecific antibody
Rheumatoid Arthritis
Active
ZZP-422 Gene therapy
Parkinson's Disease
Active
ZZP-530 ADC
Lung Cancer
Active
Scientists working in laboratory
25+
Years of Innovation

Committed to Transforming Patient Lives

Founded in 1998, Zhenzhu Pharma has grown from a small research laboratory to a global biopharmaceutical company with operations across 30 countries.

Our mission is to discover, develop, and deliver innovative medicines that address serious diseases and improve the quality of life for patients worldwide.

Scientific Excellence

World-class R&D capabilities with 500+ scientists

Patient-Centric

Every decision guided by patient needs

Global Reach

Operations in 30+ countries worldwide

Latest News

The latest announcements, press releases, and updates from Zhenzhu Pharma.

Clinical Trial Jan 15, 2026

ZZP-101 Achieves Primary Endpoint in Phase 3 Breast Cancer Trial

Positive results demonstrate significant improvement in progression-free survival compared to standard of care.

Read more
Corporate Jan 8, 2026

Zhenzhu Pharma Announces $500M Investment in New Research Facility

State-of-the-art facility will expand our capabilities in biologics and cell therapy manufacturing.

Read more
Partnership Dec 20, 2025

Strategic Collaboration with Leading European Biotech

Partnership to co-develop next-generation immunotherapies for solid tumors and hematological malignancies.

Read more

Partner With Us

Whether you're a healthcare professional, researcher, or potential partner, we'd love to hear from you.